Camilla Zimmermann, MD, PhD, FRCPC

Our research team is studying theoretical, empirical, and methodological aspects of measuring the effectiveness of specialized palliative care. This involves developing and testing potential models for the provision of palliative care, as well as validating existing measures of palliative care effectiveness and creating new ones. A particular focus is the early involvement of palliative care services in the outpatient setting. Funded by the Canadian Institutes of Health Research (CIHR), we have conducted trials of Symptom screening with Targeted Early Palliative care (STEP), versus usual care, in patients with advanced cancer and are planning a further trial of virtual STEP. Additionally, we are conducting a CIHR-funded multicentre mixed methods study using ICES data and qualitative interviews to examine the impact of COVID-19 on cancer care at the end of life. Funded by the Canadian Cancer Society and CIHR, we are also conducting a multicentre randomised trial of a joint psychological and physical symptom intervention to improve patient well-being and symptom control in patients with acute leukemia.

Pilot trial of virtual and in-person Symptom screening with Targeted Early Palliative care (STEP2)

Study Status: Active
Study Purpose: The purpose of this study is to determine if our virtual and in-person “Symptom screening with Targeted Early Palliative care” (STEP2) intervention is practical, and how a larger study should be planned.
Background: Palliative care teams are experts in pain and symptom care and focus on improving quality of life for patients with serious illness and their families. However, due to limited resources, most patients do not have early access to outpatient palliative care alongside their usual cancer care. Our team has developed a new way to identify patients with the greatest need for early palliative care (i.e. those with higher symptom scores). This system is called STEP (Symptom screening with Targeted Early Palliative care). The system uses electronic information patients report about their symptoms before each oncology clinic visit.
Study Methods: Study participants include adult patients with advanced cancer who attend medical oncology clinics at the Princess Margaret Cancer Centre and who have not yet been referred to a palliative care team. Patients who consent to participate will complete questionnaires about their quality of life, symptom control, mood, satisfaction with care, anxiety, and general health status. Questionnaires are completed at the start of the study and after 2, 4 and 6 months. Patients are asked to complete a short questionnaire about their symptoms online up to 48 hours ahead of their oncology visits. Patients who report moderate to high symptom scores at any time during the 6 months are enrolled in the study. The online tool emails the study team automatically. A study nurse will then call these patients to discuss their symptoms and offer a referral for an in-person or virtual visit to the outpatient palliative care clinic at the Princess Margaret. The outpatient palliative care team can help with pain and symptom management, coping and support, arranging care in the home as needed, and planning for the future, alongside their usual cancer care. Those who agree to this referral are offered at least monthly in-person and/or virtual palliative care clinic follow-up visits. This continues until the study ends and is based on patient needs and care provider preference. Additionally, all participants will be offered a chance to participate in a one-time one-on-one study interview with a study staff member during the study. These interviews will explore factors patients considered (or would consider) when deciding to accept or defer the outpatient palliative care clinic referral.
Health Conditions: Cancer,Palliative Care

 

For a list of Dr. Zimmermann's publications, please visit PubMed, Scopus or ORCID.


Head, Department of Supportive Care, Princess Margaret Cancer Centre
Head, Division of Palliative Care, University Health Network
Harold and Shirley Lederman Chair in Palliative Care and Psychosocial Oncology
Professor of Medicine, University of Toronto